Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alacrity Biosciences Inc.

This article was originally published in Start Up

Executive Summary

Alacrity's strategy is to in-license products that have particular promise in key ophthalmic indications, such as dry eye, glaucoma, and retinal disease. According to its founders, its specialty is recognizing the potential of these products, licensing them in, and taking them through the development process--formulation, preclinical toxicology, clinical development--everything that's needed to take a drug to the FDA and other regulatory agencies.
Advertisement

Related Content

Start-Up Previews (09/2007)
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Start-Up Previews (09/2007)

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel